Genmab A/S GENMAB ORD SHS/ DK0010272202 /
2024-08-28 4:59:57 PM | Chg. +5.00 | Volume | Bid2024-08-28 | Ask2024-08-28 | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
1,867.00DKK | +0.27% | 2,862 Turnover: 5.34 mill. |
-Bid Size: - | -Ask Size: - | 123.36 bill.DKK | - | 28.02 |
GlobeNewswire
08-19
TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults wit...
GlobeNewswire
06-28
Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Re...
GlobeNewswire
05-21
BioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy Candidates at the ASCO A...
GlobeNewswire
04-30
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervica...
GlobeNewswire
04-03
Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio
GlobeNewswire
03-20
BioNTech Announces Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
GlobeNewswire
01-09
BioNTech Outlines 2024 Strategic Priorities at the 42nd Annual J.P. Morgan Healthcare Conference
GlobeNewswire
2023-11-06
BioNTech Announces Third Quarter 2023 Financial Results and Corporate Update
GlobeNewswire
2023-10-17
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2023
GlobeNewswire
2023-09-25
Genmab Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or...